Under the terms of the agreement, PPD will analyze Merck samples with its proprietary proteomic analysis platform to identify candidate biological markers for its therapeutic business.
Additional terms of the agreement were not disclosed.
A PPD spokeswoman told GenomeWeb News that the agreement has extended the collaboration to PPD following its acquisition of SurroMed in January, but the relationship with Merck is non-exclusive.
SurroMed had an ongoing collaboration with Merck for its biomarker discovery services. "We had a relationship and we're taking it one step further," the PPD spokesperson said.
PPD said that its technology can be used to analyze samples for novel or known biomarkers, in the presence or absence of a drug, in order to evaluate the efficacy of the drug.